2 recruiting, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow RP2: new trials by email Literature Review of RP2 trials Research Report on RP2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma RP2, 5-Fluorouracil, Leucovorin - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 34 | 2027-04-01 | 2026-11-04 |
| RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2026-08-11 | 2026-10-01 | |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma RP2, Ipilimumab, Nivolumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Recruiting | Replimune, Inc. | 280 | 2024-12-17 | 2026-04-02 |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC RP2, Bevacizumab, Atezolizumab - Hepatocellular Carcinoma, Biliary Tract Cancer | Phase 2 | Recruiting | Replimune, Inc. | 60 | 2024-08-01 | 2026-04-02 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors RP2, nivolumab - Cancer | Phase 1 | Active not recruiting | Replimune, Inc. | 36 | 2019-10-17 | 2026-02-27 |
Uveal Melanoma (2) · Adenocarcinoma Of Esophagus (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Replimune, Inc. (4) · Abramson Cancer Center at Penn Medicine (1) · City of Hope Medical Center (1)
United States (5) · United Kingdom (2) · Australia (1) · Spain (1)
Gary Vanasse, MD (3) · Charles B Nguyen (1) · Rahul Marpadga, MD MPH (1) · William Chapin, MD, MSCE (1)
P30CA033572 (1)